Biotech RadarJobs updated

COMPANY

Nkarta Therapeutics

HQ: South San Francisco, CA source · nkartatx.com ↗ · West Coast

Clinical Phase 2

5 open jobs · last seen Oct 23, 2026 · 5 sources

Keywords: immunology autoimmune diseases cell therapy autoimmune disease Systemic Sclerosis Idiopathic Inflammatory Myopathies Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Rheumatoid Arthritis Lupus Nephritis Primary Membranous Nephropathy Non-Hodgkin Lymphoma B-cell Acute Lymphoblastic Leukemia Large B-cell Lymphoma Mantle Cell Lymphoma Indolent Lymphoma Waldenstrom Macroglobulinemia Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Aggressive Lymphoma Large-cell Lymphoma Relapsed/Refractory AML Adult AML Refractory Myelodysplastic Syndromes NKX019 NKX101 - CAR NK cell therapy

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

5Open jobs4Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Associate General CounselSouth San Francisco, CAOct 16, 2026Oct 17, 2026
Associate Director, Clinical Trial OperationsSouth San Francisco, CASep 18, 2026Oct 5, 2026
Senior Manager/Associate Director, Information TechnologySouth San FranciscoSep 17, 2026Oct 5, 2026
Director, Clinical Trial OperationsSouth San Francisco, CAAug 18, 2026Oct 5, 2026
Principal Scientist, BioinformaticsSouth San Francisco, California, United StatesMay 15, 2026Oct 5, 2026

See all 5 jobs

Timeline

  1. Board tracked Radar started tracking this company’s job board (5 open jobs at last check). source ↗
  2. Trial start 1: A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2) source ↗
  3. Trial start 1: A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) source ↗
  4. Trial start Phase 1: NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers source ↗
  5. Trial start Phase 1: NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 5

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Associate General CounselSouth San Francisco, CAOct 16, 2026Oct 17, 2026Not stated
Associate Director, Clinical Trial OperationsSouth San Francisco, CASep 18, 2026Oct 5, 2026Senior
Senior Manager/Associate Director, Information TechnologySouth San FranciscoSep 17, 2026Oct 5, 2026Senior
Director, Clinical Trial OperationsSouth San Francisco, CAAug 18, 2026Oct 5, 2026Senior
Principal Scientist, BioinformaticsSouth San Francisco, California, United StatesMay 15, 2026Oct 5, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT06733935A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)1RecruitingNov 4, 20242028-10 (estimated)
NCT06557265A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)1RecruitingJun 13, 20242027-04 (estimated)
NCT05020678NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell CancersPhase 1Active, not recruitingAug 20, 2021Mar 31, 2025 (actual)
NCT04623944NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDSPhase 1Active, not recruitingSep 21, 2020Oct 2, 2024 (actual)
Feedback